ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome.
George
James N
JN
The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA.
D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000328:Adult; D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology* / Q000276:immunology; D003937:Diagnosis, Differential; D004198:Disease Susceptibility; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000201:enzymology / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007249:Inflammation / Q000150:complications; D007676:Kidney Failure, Chronic / Q000209:etiology; D008666:Metalloendopeptidases / Q000172:deficiency* / Q000235:genetics / Q000276:immunology / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000150:complications; D010951:Plasma Exchange; D010956:Plasmapheresis; D010973:Platelet Adhesiveness; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000201:enzymology / Q000209:etiology / Q000276:immunology; D011499:Protein Processing, Post-Translational; D011697:Purpura, Thrombotic Thrombocytopenic / Q000151:congenital / Q000175:diagnosis / Q000201:enzymology / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D012307:Risk Factors; D022641:Shiga Toxin 2 / Q000633:toxicity; D014841:von Willebrand Factor / Q000378:metabolism*
D001323:Autoantibodies; D022641:Shiga Toxin 2; D014841:von Willebrand Factor; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human